[go: up one dir, main page]

WO2020076738A3 - Composés à liaison protéinique - Google Patents

Composés à liaison protéinique Download PDF

Info

Publication number
WO2020076738A3
WO2020076738A3 PCT/US2019/055067 US2019055067W WO2020076738A3 WO 2020076738 A3 WO2020076738 A3 WO 2020076738A3 US 2019055067 W US2019055067 W US 2019055067W WO 2020076738 A3 WO2020076738 A3 WO 2020076738A3
Authority
WO
WIPO (PCT)
Prior art keywords
bind
rapamycin
compounds
proteins
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/055067
Other languages
English (en)
Other versions
WO2020076738A2 (fr
Inventor
Joseph Henri Bayle
Slawomir Szymanski
Matthew Robert Collinson-Pautz
Steven Mark TOLER
David Michael Spencer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellicum Pharmaceuticals Inc
Original Assignee
Bellicum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellicum Pharmaceuticals Inc filed Critical Bellicum Pharmaceuticals Inc
Publication of WO2020076738A2 publication Critical patent/WO2020076738A2/fr
Publication of WO2020076738A3 publication Critical patent/WO2020076738A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La technologie concerne en partie des composés qui se lient à des protéines. Dans certains exemples, les composés peuvent se lier à des protéines de liaison à la rapamycine. Dans certains exemples, les composés peuvent se lier à des protéines cellulaires et/ou des formes de variants de protéines cellulaires de liaison à la rapamycine et/ou à des analogues de la rapamycine. Dans certains exemples, les composés se lient à des protéines multimériques de liaison à la rapamycine et/ou à des analogues de la rapamycine, par exemple une protéine FKBP12 (et/ou des variants de celle-ci) et un polypeptide mTOR et/ou un domaine tel que FRB, et/ou des variants de celui-ci. L'invention concerne des composés comprenant ceux ayant une structure de formule A, dans laquelle les fractions R20, R21 et R22 sont décrites ici.
PCT/US2019/055067 2018-10-12 2019-10-07 Composés à liaison protéinique Ceased WO2020076738A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744813P 2018-10-12 2018-10-12
US62/744,813 2018-10-12

Publications (2)

Publication Number Publication Date
WO2020076738A2 WO2020076738A2 (fr) 2020-04-16
WO2020076738A3 true WO2020076738A3 (fr) 2020-05-22

Family

ID=70165276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/055067 Ceased WO2020076738A2 (fr) 2018-10-12 2019-10-07 Composés à liaison protéinique

Country Status (1)

Country Link
WO (1) WO2020076738A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7382353B2 (ja) 2018-06-15 2023-11-16 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体およびその使用
KR102705165B1 (ko) 2019-01-22 2024-09-11 에오비안 파마슈티컬스, 인크. Mtorc 조절제 및 이의 용도
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用
CN119954829A (zh) 2020-03-27 2025-05-09 艾奥维安制药公司 Mtorc1调节剂及其用途
EP4185590A2 (fr) 2020-07-21 2023-05-31 Aeovian Pharmaceuticals, Inc. Modulateurs de mtorc1 et leurs utilisations
CN114539288B (zh) * 2020-11-24 2024-01-30 鲁南制药集团股份有限公司 一种依维莫司的制备方法
AU2022209863A1 (en) * 2021-01-22 2023-09-07 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170831A1 (en) * 1984-12-03 2003-09-11 Fujisawa Pharmaceutical Co. Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US20090239855A1 (en) * 2004-12-20 2009-09-24 Wyeth Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders
US20090253732A1 (en) * 2004-08-11 2009-10-08 Biotica Technology Limited Production Of Polyketides And Other Natural Products
US20160176893A1 (en) * 2013-07-09 2016-06-23 Isomerase Therapeutics Limited Rapamycin analogues and their pharmaceutical use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170831A1 (en) * 1984-12-03 2003-09-11 Fujisawa Pharmaceutical Co. Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US20090253732A1 (en) * 2004-08-11 2009-10-08 Biotica Technology Limited Production Of Polyketides And Other Natural Products
US20090239855A1 (en) * 2004-12-20 2009-09-24 Wyeth Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders
US20160176893A1 (en) * 2013-07-09 2016-06-23 Isomerase Therapeutics Limited Rapamycin analogues and their pharmaceutical use

Also Published As

Publication number Publication date
WO2020076738A2 (fr) 2020-04-16

Similar Documents

Publication Publication Date Title
WO2020076738A3 (fr) Composés à liaison protéinique
WO2020068752A8 (fr) PROTÉINES DE LIAISON SIRPα ET MÉTHODES D'UTILISATION DE CELLES-CI
EP4524148A3 (fr) Compositions de protéines anti-vegf et procédés de production associés
EP4382167A3 (fr) Composés comprenant un lieur pour augmenter la stabilité du transcyclooctène
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
EP4559323A3 (fr) Sources de protéines d'origine non animale présentant des propriétés fonctionnelles
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112017025975A2 (pt) ?composto, composição, e, método para induzir degradação de uma proteína alvo em uma célula?.
WO2015006337A3 (fr) Compositions et procédés permettant d'augmenter la demi-vie d'une protéine dans un sérum
MX382321B (es) Nuevo polipéptido con afinidad por pd-l1.
EP3543335A3 (fr) Protéines de fusion d'intéine solubles et procédés de purification de biomolécules
EP2203468B8 (fr) Nouveaux peptides antiviraux qui empêchent la liaison du virus à dlc8
BR112022003357A2 (pt) Compostos heterocíclicos
BR112014024751A2 (pt) antígenos de clostridium difficile
AU2017269839A1 (en) Methods for treatment of refractory generalized myasthenia gravis
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
WO2020221881A3 (fr) Solution d'imprégnation sans bore pour une mèche et mèche sans bore
MX2022007158A (es) Anticuerpos anti-ly6g6d y metodos de uso.
PH12022550698A1 (en) Treatment of alcoholic hepatitis
WO2019094533A8 (fr) Agents de liaison à angptl8 et leurs méthodes d'utilisation
WO2015083125A3 (fr) Anticorps reconnaissant l'iapp
WO2021081437A3 (fr) Compositions comprenant des enveloppes de vih opt v2
CA2832695C (fr) Composes se liant a l'anneau beta bacterien
EP4257193A3 (fr) Protéines de liaison trispécifiques et/ou trivalentes
WO2020115083A3 (fr) Amphipols

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19872073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19872073

Country of ref document: EP

Kind code of ref document: A2